283 related articles for article (PubMed ID: 37350955)
1. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma.
Su J; Zhou L; Zhang Z; Xiao X; Qin Y; Zhou X; Huang T
Front Immunol; 2023; 14():1146738. PubMed ID: 37350955
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
[No Abstract] [Full Text] [Related]
3. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.
Raimondi A; Sepe P; Zattarin E; Mennitto A; Stellato M; Claps M; Guadalupi V; Verzoni E; de Braud F; Procopio G
Front Oncol; 2020; 10():1644. PubMed ID: 32903369
[TBL] [Abstract][Full Text] [Related]
4. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
5. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
Lee HW
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
7. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions.
Rambhia A; Patel RD; Okhawere KE; Korn TG; Badani KK
Urol Oncol; 2021 Oct; 39(10):664-677. PubMed ID: 34312081
[TBL] [Abstract][Full Text] [Related]
9. Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Hara T; Miyake H; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):363-369. PubMed ID: 28169111
[TBL] [Abstract][Full Text] [Related]
10. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
11. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
Labriola MK; Batich KA; Zhu J; McNamara MA; Harrison MR; Armstrong AJ; George DJ; Zhang T
Clin Genitourin Cancer; 2019 Jun; 17(3):e513-e521. PubMed ID: 30858035
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma.
Sepe P; Mennitto A; Corti F; Procopio G
Immunotargets Ther; 2020; 9():273-288. PubMed ID: 33224904
[TBL] [Abstract][Full Text] [Related]
14. Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma.
Stühler V; Rausch S; Maas JM; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Sep; 21(9):1215-1226. PubMed ID: 33576709
[TBL] [Abstract][Full Text] [Related]
15. [Mode of action, new targets and potential biomarkers in modern immunotherapy].
Bedke J; Stühler V; Todenhöfer T; Stenzl A
Urologe A; 2018 Nov; 57(11):1301-1308. PubMed ID: 30350128
[TBL] [Abstract][Full Text] [Related]
16. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
18. Emerging resistance
Roy AM; George S
Cancer Drug Resist; 2023; 6(3):642-655. PubMed ID: 37842239
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
Han SC; Yin HQ; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
